MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$36,394K
Free Cash flow
$42,967K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturity of short-...
Stock-based compensation
Proceeds from the exercise of co...
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Total research and development
Total selling and marketing
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
150,321
139,071
140,636
376,509
Laboratory supplies and reagents expense
13,847
12,314
14,150
43,134
Sample collection expense
3,644
3,288
3,038
9,398
Compensation expense
9,858
9,804
6,705
17,906
Other cost
5,883
4,937
5,638
14,017
Allocation of facilities and it expenses
3,077
2,963
3,587
9,989
Cost of revenue-Testing
36,309
33,306
33,118
94,444
Product costs
1,985
1,401
1,923
1,864
License fees and royalties
336
313
318
888
Other cost
190
174
368
2,980
Allocation of facilities and it expenses
4
3
12
454
Cost of revenue-Product
2,515
1,891
2,621
6,186
Compensation expense
0
0
2
3,318
Other cost
207
8
215
3,118
Allocation of facilities and it expenses
0
0
0
925
Cost of revenue-Biopharmaceutical And Other
207
8
217
7,361
Intangible asset amortization - cost of revenue
2,741
2,707
2,707
7,959
Gross profit
108,549
101,159
101,973
260,559
Compensation expense
-
15,547
9,944
27,840
Direct expense
-
4,198
5,650
10,946
Other research and development expenses
-
5,460
3,214
5,278
Allocation of facilities and it expenses
-
1,893
2,041
5,901
Total research and development
29,442
27,098
20,849
49,965
Compensation expense
-
19,972
16,995
52,214
Direct expense
-
1,455
1,999
3,564
Other selling and marketing expenses
-
4,561
4,063
10,880
Allocation of facilities and it expenses
-
1,168
2,883
7,567
Total selling and marketing
28,263
27,156
25,940
74,225
Compensation expense
-
16,236
20,788
62,121
Other general and administrative expenses
-
13,471
5,102
56,132
Allocation of facilities and it expenses
-
-6,027
-8,523
-24,836
Total general and administrative
27,443
23,680
17,367
93,417
Impairment of assets
0
-
0
20,505
Intangible asset amortization - operating expenses-Intangible Asset Amortization
421
579
622
1,865
Other income, net
3,543
7,328
3,439
6,985
Income tax provision
1,033
1,267
-515
2,363
Net income
25,490
28,707
41,149
19,137
Depreciation and amortization
4,838
5,430
5,298
5,266
Loss on disposal of property, plant and equipment
-1
-366
0
0
Stock-based compensation
14,086
12,761
10,901
10,757
Deferred income taxes
1
-10
-568
-87
Noncash lease expense
704
732
702
689
Non-cash loss on deconsolidation of subsidiary
-
-
-2,845
-3,863
Revaluation of acquisition-related contingent consideration
-318
-350
-12,582
166
Effect of foreign currency on operations
-11
80
-11
-1,205
Amortization of discount on short-term investments
723
614
651
2,619
Impairment loss
0
-
0
0
Accounts receivable
4,162
5,567
-3,150
-425
Supplies and inventory
-
-
219
-221
Supplies
1,240
870
-
-
Prepaid expenses and other current assets
1,123
1,306
-4,362
956
Other assets
319
132
-194
-1,720
Operating lease liabilities
772
-319
-799
-495
Accounts payable
1,171
2,587
-492
-3,660
Accrued liabilities and deferred revenue
6,637
-6,120
-718
9,125
Net cash provided by operating activities
45,826
35,215
52,583
44,757
Loss on deconsolidation of subsidiary - cash
-
-
2,845
-
Acquisition of c2i, net of cash acquired
-
-
0
0
Purchase of short-term investments
59,999
124,999
50,000
0
Proceeds from sale of short-term investments
-
-
0
-
Proceeds from maturity of short-term investments
50,935
-
51,195
51,055
Issuance of loan receivable
1,622
-
-
-
Purchases of property, plant and equipment
2,859
2,962
3,780
2,792
Net cash used in investing activities
-13,545
-127,961
-5,430
48,263
Payment of contingent consideration for acquisition
-
-
0
-
Payment of taxes on vested restricted stock units
4,294
9,364
3,659
2,814
Proceeds from the exercise of common stock options and employee stock purchases
8,433
2,735
3,510
5,791
Net cash used in financing activities
4,139
-6,629
-149
2,977
Decrease in cash, cash equivalents and restricted cash
36,420
-99,375
47,004
95,997
Effect of foreign currency on cash, cash equivalents and restricted cash
-26
-58
12
60
Net decrease in cash, cash equivalents and restricted cash
36,394
-99,433
47,016
96,057
Cash, cash equivalents and restricted cash at beginning of period
264,793
364,226
317,210
240,631
Cash, cash equivalents and restricted cash at end of period
301,187
264,793
364,226
317,210
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Total revenue
$150,321K
Gross profit
$108,549K
Other income, net
$3,543K
Canceled cashflow
$41,772K
Net income
$25,490K
(320.14%↑ Y/Y)
Stock-based compensation
$14,086K
(-35.81%↓ Y/Y)
Accrued liabilities and
deferred revenue
$6,637K
(417.41%↑ Y/Y)
Proceeds from the
exercise of common stock...
$8,433K
(76.39%↑ Y/Y)
Canceled cashflow
$86,602K
Depreciation and
amortization
$4,838K
(-55.41%↓ Y/Y)
Accounts payable
$1,171K
(-62.38%↓ Y/Y)
Operating lease
liabilities
$772K
(165.09%↑ Y/Y)
Noncash lease expense
$704K
(-56.00%↓ Y/Y)
Effect of foreign
currency on operations
-$11K
(-100.22%↓ Y/Y)
Deferred income taxes
$1K
(-98.65%↓ Y/Y)
Loss on disposal of
property, plant and...
-$1K
(93.33%↑ Y/Y)
Cost of
revenue-Testing
$36,309K
Intangible asset
amortization - cost of revenue
$2,741K
Cost of
revenue-Product
$2,515K
Cost of
revenue-Biopharmaceutical And Other
$207K
Net cash provided by
operating activities
$45,826K
(17.60%↑ Y/Y)
Net cash used in
financing activities
$4,139K
(158.71%↑ Y/Y)
Canceled cashflow
$7,885K
Canceled cashflow
$4,294K
Total research and
development
$29,442K
Total selling and
marketing
$28,263K
Total general and
administrative
$27,443K
Income tax provision
$1,033K
Intangible asset
amortization - operating...
$421K
Laboratory supplies and
reagents expense
$13,847K
Compensation expense
$9,858K
Other cost
$5,883K
Sample collection
expense
$3,644K
Allocation of facilities
and it expenses
$3,077K
Product costs
$1,985K
License fees and
royalties
$336K
Other cost
$190K
Allocation of facilities
and it expenses
$4K
Other cost
$207K
Decrease in cash, cash
equivalents and restricted...
$36,420K
(280.97%↑ Y/Y)
Canceled cashflow
$13,545K
Accounts receivable
$4,162K
(-2.83%↓ Y/Y)
Supplies
$1,240K
Prepaid expenses and
other current assets
$1,123K
(-79.43%↓ Y/Y)
Amortization of discount on
short-term investments
$723K
Other assets
$319K
(-77.03%↓ Y/Y)
Revaluation of
acquisition-related contingent...
-$318K
(88.95%↑ Y/Y)
Proceeds from maturity of
short-term investments
$50,935K
(-0.25%↓ Y/Y)
Payment of taxes on
vested restricted...
$4,294K
(-63.71%↓ Y/Y)
Net decrease in
cash, cash...
$36,394K
(286.85%↑ Y/Y)
Canceled cashflow
$26K
Net cash used in
investing activities
-$13,545K
(73.97%↑ Y/Y)
Canceled cashflow
$50,935K
Effect of foreign
currency on cash, cash...
-$26K
(-104.02%↓ Y/Y)
Purchase of short-term
investments
$59,999K
(-40.00%↓ Y/Y)
Purchases of property,
plant and equipment
$2,859K
(-7.92%↓ Y/Y)
Issuance of loan
receivable
$1,622K
Buy us a coffee
VERACYTE, INC. (VCYT)
VERACYTE, INC. (VCYT)